SMART (simultaneous modulated accelerated radiotherapy) for locally advanced nasopharyngeal carcinomas

Head and Neck

Volumn 30, Issue 2, 2008, Pages 159-169

  Woong, Sub Koom ^a   Tae, Hyun Kim ^a   Kyung, Hwan Shin ^a   Hong, Ryull Pyo ^a   Kim, Joo Young ^a   Dae, Yong Kim ^a   Yoon, Myonggeun ^a   Sung, Yong Park ^a   Dae, Ho Lee ^a   Jun, Sun Ryu ^a   Yoo, Seok Jung ^a   Sang, Hyun Lee ^a   Cho, Kwan Ho ^a  

^a National Cancer Center   (South Korea)

Author keywords

Nasopharyngeal carcinoma; Simultaneous modulated accelerated radiotherapy (SMART); Survival; Toxicity; Tumor control

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN DAMAGE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; CRANIAL NEUROPATHY; FEMALE; FOLLOW UP; HUMAN; LHERMITTE DUCLOS DISEASE; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PHARYNGITIS; PRIORITY JOURNAL; RADIATION DOSE; SKIN ATROPHY; SKIN EXFOLIATION; SKIN TOXICITY; SPINAL CORD LESION; TELANGIECTASIA; TREATMENT OUTCOME; TUMOR VOLUME; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; XEROSTOMIA;

EID: 39149095974     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20667     Document Type: Article

References (26)

1. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol 1998;16:1310-1317.
2. Chan ATC, Leung SF, Ngan RKC, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005;97:536-539.
3. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003;21:631-637.
4. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with AJCC/UICC stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005;23:6730-6738.
5. Lee AWM, Lau WH, Tung SY, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma; NPC-9901 trial by the Hong Kong nasopharyngeal cancer study group. J Clin Oncol 2005;23:6966-6975.
6. Butler EB, Teh BS, Grant WH, et al. Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 1999;45:21-32.
7. Lauve A, Morris M, Schmidt-Ullrich R, et al. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas. II. Clinical results. Int J Radiat Oncol Biol Phys 2004;60:374-387.
8. Gregoire V, Levendag P, Ang KK, et al. CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines. Radiother Oncol 2003;69:227-236.
9. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-1346.
10. Mell LK, Roeske JC, Mundt AJ. A survey of intensity-modulated radiation therapy use in the United States. Cancer 2003;98:204-211.
11. Xia P, Fu KK, Wong GW, Akazawa C, Verhey LJ. Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2000;48:329-337.
12. Hunt MA, Zelefsky MJ, Wolden S, et al. Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer. Int J Radiat Oncol Biol Phys 2001;49:623-632.
13. Cozzi L, Fogliata A, Bolsi A, Nicolini G, Bernier J. Three-dimensional conformai vs. intensity-modulated radiotherapy in head-and-neck cancer patients: comparative analysis of dosimetric and technical parameters. Int J Radiat Oncol Biol Phys 2004;58:617-624.
14. Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002;53:12-22.
15. Kam MKM, Teo PML, Chau RMC, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys 2004;60:1440-1450.
16. Withers HR, Thames HD. Dose fractionation and volume effects in normal tissues and tumors. Am J Clin Oncol 1988;11:313-329.
17. Horiot JC, Bontemps P, van den Bogaert W, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997;44:111-121.
18. Fu KK, Pajak TF, Trotti A et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
19. Overgaard J, Sand Hansen H, Overgaard M, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of the head and neck: DAHANCA 6 and 7 randomized controlled trial. Lancet 2003;362:933-940.
20. Withers HR, Taylor JMG, Macejewski B. The hazard of accelerated tumor donogen repopulation during radiotherapy. Acta Oncol 1988;27:131-146.
21. Lin JC, Chen KY, Jan JS, Hsu CY. Partially hyperfractionated accelerated radiotherapy and concurrent chemotherapy for advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1996;36:1127-1136.
22. Wolden SL, Zelefsky MJ, Kraus DH, et al. Accelerated concomitant boost radiotherapy and chemotherapy for advanced nasopharyngeal carcinoma. J Clin Oncol 2001; 19:1105-1110.
23. Adelstein DJ, Saxton JP, Lavertu P, et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck 1997;19:567-575.
24. Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318-1324.
25. Eisbruch A, Ten Haken RK, Kim HM, Marsh LH, Ship JA. Dose, volume, and function relationships in parotid salivary glands following conformai and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 1999;45:577-587.
26. Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:695-704.